Barth Syndrome Drug: FDA Decision & Next Steps
- Stealth BioTherapeutics faces another setback in its decade-long effort to gain FDA approval for its Barth syndrome drug, elamipretide.
- Elamipretide targets Barth syndrome, a rare genetic disorder characterized by an enlarged heart, muscle weakness, and reduced life expectancy.
- Despite these hurdles, Stealth biotherapeutics achieved a meaningful milestone last October when a majority of an FDA advisory committee recommended approval after navigating various agency divisions.
The FDA has rejected Stealth BioTherapeutics’ elamipretide, dashing hopes for an ultra-rare disease drug and delaying potential treatment for Barth syndrome patients. This decision follows years of effort and setbacks for the company,which has faced challenges in generating sufficient clinical trial data for this rare genetic disorder. The rejection of this primary_keyword drug not only impacts the approximately 150 individuals in the U.S. affected by Barth syndrome, but also raises questions about the company’s financial stability. Stealth BioTherapeutics had previously achieved a positive milestone with an FDA advisory committee suggestion, making this rejection unexpected. News Directory 3 is following this closely.What are the next steps for elamipretide, and how will this impact access to secondary_keyword treatment? Discover what’s next …
FDA Rejects Stealth BioTherapeutics’ Barth Syndrome Drug for Ultra-Rare Disease
Updated May 29, 2025
Stealth BioTherapeutics faces another setback in its decade-long effort to gain FDA approval for its Barth syndrome drug, elamipretide. The recent regulatory rejection not only delays access to this crucial ultra-rare disease drug but also puts a strain on the company’s financial stability.
Elamipretide targets Barth syndrome, a rare genetic disorder characterized by an enlarged heart, muscle weakness, and reduced life expectancy. This condition affects approximately 150 individuals in the United States. The limited patient population has presented challenges for both Stealth BioTherapeutics and the FDA in generating sufficient clinical trial data to support the drug’s approval.
Despite these hurdles, Stealth biotherapeutics achieved a meaningful milestone last October when a majority of an FDA advisory committee recommended approval after navigating various agency divisions. However, the FDA missed its initial deadline in January and a subsequent one in April to finalize its review, raising concerns about potential factors influencing the delay.
What’s next
The future of elamipretide and Stealth BioTherapeutics’ involvement remains uncertain as the company evaluates its options following the FDA’s rejection. Patients with barth syndrome continue to await potential treatments.